Fabry disease is a genetic condition in which the body lacks a key enzyme needed to break down certain fatty substances. Without enough of this enzyme, a type of fat called globotriaosylceramide builds up inside cells throughout the body, gradually damaging the kidneys, heart, brain, and nervous system. It was once considered extremely rare, with estimates of 1 in 40,000 to 1 in 170,000 live births, but newborn screening programs in Italy, Taiwan, and Japan suggest it may be far more common, with rates as high as 1 in 3,100 to 1 in 8,800 male newborns.
How Fabry Disease Develops
Every cell in your body contains tiny compartments called lysosomes that act like recycling centers, breaking down waste materials so the cell can reuse or dispose of them. One of the tools lysosomes rely on is an enzyme called alpha-galactosidase A. In Fabry disease, mutations in the GLA gene mean this enzyme is either missing or barely functional. Without it, fatty molecules accumulate inside lysosomes instead of being cleared away. Over years and decades, this buildup damages blood vessel walls, nerve fibers, and organ tissue.
The severity depends on how much enzyme activity remains. In classic Fabry disease, enzyme activity is essentially zero, and symptoms begin in childhood and affect multiple organs. In non-classic (or late-onset) forms, some enzyme activity is preserved. People with non-classic disease may have milder symptoms that are frequently limited to the heart, sometimes not appearing until middle age.
Inheritance and Who It Affects
The GLA gene sits on the X chromosome, which means the inheritance pattern differs between males and females. Males have one X chromosome, so a single mutated copy is enough to cause the disease. Females have two X chromosomes, and whether they develop symptoms depends largely on a process called X-inactivation: in each cell, one X chromosome is randomly silenced. If the healthy copy happens to be silenced in many cells, a woman can experience significant disease. If the mutated copy is silenced more often, she may have few or no symptoms.
Because of this variability, Fabry disease was historically described as a condition affecting only males. That understanding has changed. Both males and females develop Fabry disease, though females tend to have a later onset and a wider range of severity.
Early Symptoms in Childhood
The earliest signs of Fabry disease typically appear in childhood, often between ages 5 and 15, and they are easy to misattribute to other conditions or dismiss entirely.
- Burning pain in the hands and feet. Called acroparesthesia, this is one of the hallmark early symptoms. It presents as chronic tingling or burning, sometimes with acute episodes of severe pain lasting minutes to days. Physical exercise, heat, and fever are the most common triggers. The pain results from damage to small nerve fibers.
- Reduced or absent sweating. Nerve damage and fatty deposits in sweat glands lead to hypohidrosis, reported in 93% of affected boys and 25% of affected girls in one European study. The median age of onset is around 13 in males and 29 in females. This makes it difficult to regulate body temperature, leading to heat intolerance.
- Small dark-red skin spots. These raised lesions, called angiokeratomas, are clusters of dilated blood vessels near the skin surface. They tend to appear between the navel and the knees and may be the earliest visible sign of the disease, showing up at an average age of about 13.5 years.
- Digestive problems. Abdominal cramping, bloating, diarrhea, and nausea are common in childhood and often lead to misdiagnosis with irritable bowel syndrome or other gastrointestinal conditions.
- Eye changes. Faint, whorl-shaped opacities in the cornea can be detected during an eye exam even in young children. These rarely affect vision but are a useful diagnostic clue.
Major Organ Damage Over Time
If Fabry disease goes unrecognized, the ongoing fat accumulation progressively damages three organ systems that determine long-term outcomes.
Kidneys
Protein spilling into the urine (proteinuria) is often the first measurable sign of kidney involvement and can appear in early adulthood. Without treatment, kidney function declines steadily, and some patients progress to kidney failure requiring dialysis or transplantation.
Heart
The heart muscle thickens as fatty material builds up in cardiac cells, a condition known as left ventricular hypertrophy. This can lead to abnormal heart rhythms, valve problems, and eventually heart failure. In people with non-classic Fabry disease, the heart is frequently the only organ significantly affected, and the thickening is sometimes mistaken for other causes of an enlarged heart.
Brain and Blood Vessels
Damage to blood vessel walls in the brain increases the risk of transient ischemic attacks (mini-strokes) and full strokes. These events can occur surprisingly early, sometimes in a person’s 20s or 30s. The combination of kidney disease, heart thickening, and stroke in a young adult is a pattern that should raise suspicion for Fabry disease, though it is frequently recognized too late for treatment to be most effective.
Data from the Fabry Registry show that males with Fabry disease have a life expectancy of about 58 years, compared with roughly 75 years in the general U.S. population. Females with Fabry disease have a life expectancy of about 75 years, compared with 80 years in the general population. Cardiac and kidney complications are the leading causes of death.
How Fabry Disease Is Diagnosed
In males, the diagnosis is straightforward: a blood test measuring alpha-galactosidase A activity in plasma or white blood cells will show a clear deficiency. In females, this enzyme test is unreliable because X-inactivation can leave enzyme levels anywhere from severely low to completely normal. The only definitive way to confirm the diagnosis in a woman is genetic testing to identify the specific mutation in the GLA gene.
A blood marker called lyso-Gb3 (a breakdown product of the accumulating fat) can also help. Elevated levels serve as a stable indicator that enzyme activity is low enough to cause disease, which is particularly useful for distinguishing true Fabry disease from borderline cases where a genetic variant lowers enzyme levels only slightly. Once a mutation is identified in one family member, genetic counseling and testing of relatives can uncover others who carry the same variant.
Treatment Options
Treatment for Fabry disease works in two main ways: replacing the missing enzyme or helping the body’s own defective enzyme work better.
Enzyme replacement therapy (ERT) involves intravenous infusions of a manufactured version of alpha-galactosidase A, given every two weeks. Two forms are available (agalsidase alfa and agalsidase beta), and both aim to clear the accumulated fat from cells and slow organ damage. ERT has been the standard treatment since the early 2000s, and starting it before major organ damage occurs produces the best outcomes. The infusions typically take a few hours and are given in a clinic or, after initial doses, sometimes at home.
For patients whose specific genetic mutation produces a misfolded but partially functional enzyme, an oral medication called migalastat offers an alternative. Migalastat acts as a molecular chaperone: it binds to the misshapen enzyme and helps it fold into the correct shape so it can reach the lysosome and do its job. Taken as a capsule every other day, it is the only oral treatment for Fabry disease and has been available in Europe since 2016 and in the United States since 2018. Not everyone is eligible, because the drug only works with certain “amenable” mutations.
Managing Pain and Daily Triggers
Beyond disease-specific therapy, managing the chronic and episodic pain of Fabry disease is a major part of daily life. The most important triggers are heat, physical exertion, and fever. Practical strategies that can reduce pain episodes include using air conditioning to avoid overheating, staying well hydrated, treating fevers and infections promptly, and removing shoes and socks during a pain flare to cool the extremities. Some people also benefit from pain-relieving medications tailored to neuropathic pain, though standard over-the-counter painkillers are often ineffective for this type of nerve-related discomfort.
Exercise still matters for cardiovascular and mental health, but it needs to be approached carefully. Shorter sessions, cooler environments, and plenty of water help many people stay active without triggering severe pain crises.
Gene Therapy on the Horizon
The first completed gene therapy clinical trial for Fabry disease, the Canadian FACTs trial, recently reported five-year results. Researchers took patients’ own blood stem cells, inserted a working copy of the GLA gene using a modified virus, and infused the corrected cells back. The idea is that these cells circulate throughout the body, continuously producing the missing enzyme and even sharing it with neighboring cells that weren’t corrected.
All five patients in the trial showed durable enzyme production for more than five years after a single treatment. Three of the five were able to stop their biweekly enzyme replacement infusions entirely. Kidney symptoms stabilized in all patients, and the key blood marker of fat accumulation dropped significantly in four of five. These results are from a small trial, but they suggest that a one-time treatment could eventually replace lifelong infusions for some patients.